Ra's zilucoplan meets in Phase II for generalized myasthenia gravis, company raises $130M

Ra Pharmaceuticals Inc. (NASDAQ:RARX) said on Dec. 10 that zilucoplan (formerly RA101495 SC) met the primary and key secondary endpoints in a Phase II trial to treat generalized myasthenia gravis. The company plans

Read the full 336 word article

User Sign In